Journal articles: 'Coenzima Q10'

1

Silva, Fabiana Barreiro de Freitas, Hyllana Catarine Dias de Medeiros, Marieli Guelfi, Andréia Tieme de Santana, and Fábio Erminio Mingatto. "Efeito da coenzima Q10 nos danos oxidativos induzidos pela L-tiroxina no músculo sóleo de ratos." Revista Brasileira de Medicina do Esporte 21, no. 2 (April 2015): 84–88. http://dx.doi.org/10.1590/1517-86922015210202158.

Full text

Abstract:

INTRODUÇÃO: os músculoesqueléticos são tecidos dinâmicos que podem alterar suas características fenotípicas proporcionando melhor adaptação funcional com estímulos variados. A L-tiroxina é um hormônio produzido pela glândula tireoide e tem sido utilizada como modelo experimental para estimulação de estresse oxidativo no músculo esquelético. A coenzima Q10 é uma provitamina lipossolúvel sintetizada endogenamente e naturalmente encontrada em alimentos como carne vermelha, peixes, cereais, brócolis e espinafre. Apresenta propriedade antioxidante e tem potencial no tratamento de doenças degenerativas e neuromusculares.OBJETIVO: avaliar o efeito protetor da coenzima Q10 no músculo sóleo de ratos frente aos danos oxidativos provocados pela L-tiroxina.MÉTODOS: os ratos foram distribuídos em quatro grupos de seis animais cada: Grupo 1 controle; Grupo 2 coenzima Q10; Grupo 3 L-tiroxina e Grupo 4 coenzima Q10 e L-tiroxina. Após a eutanásia, o sangue dos animais foi colhido e foi analisada a atividade sérica das enzimas creatina quinase CK e aspartato aminotransferase AST. No homogenato do músculo sóleo foram avaliados fatores relacionados ao estresse oxidativo.RESULTADOS: a coenzima Q10 protegeu o músculo sóleo dos danos provocados pela L-tiroxina e favoreceu a manutenção da atividade das enzimas antioxidantes glutationa redutase e glutationa peroxidase, da concentração de glutationa reduzida e oxidada, além de evitar a lipoperoxidação.CONCLUSÃO: os resultados indicam que a coenzima Q10 protege o músculo sóleo de ratos dos danos oxidativos provocados pela L-tiroxina.

APA, Harvard, Vancouver, ISO, and other styles

2

Ferreira Alfaya, Francisco Javier. "Evidencia del manejo de miopatías asociadas a estatina con coenzima Q10." Ars Pharmaceutica (Internet) 63, no. 1 (December 20, 2021): 78–91. http://dx.doi.org/10.30827/ars.v63i1.21930.

Full text

Abstract:

Introducción: La incidencia de eventos cardiovasculares fatales es muy elevada y el tratamiento con estatinas es vital para reducir este riesgo en muchos pacientes, sin embargo, sus efectos adversos sobre el músculo esquelético dificultan la adherencia o la continuación del mismo. Se ha propuesto la suplementación de coenzima Q10 para revertir mialgias asociadas a el empleo de estatinas. Los ensayos clínicos que se realizaron en los últimos 10 años obtuvieron resultados contrapuestos. El objetivo de este trabajo es revisar la evidencia sobre la eficacia del empleo de suplementos de coenzima Q10 en para mitigar las miopatías causadas por las estatinas. Metodología: Se realizó una búsqueda sistemática de la literatura publicada hasta Julio de 2020. Las bases de datos consultadas fueron MEDLINE y SCOPUS. También se consultaron instituciones como la Agencia Española del Medicamento y Productos Sanitarios (AEMPS), la European Medicines Agency (EMA) y la Food and Drug Administration (FDA). Resultados: La etiología de las mialgias asociadas a estatinas sigue siendo desconocida y la evidencia encontrada en los ensayos clínicos y metaanalisis obtuvieron conclusiones dispares. La European Medicine Agency (EMA) solo considera el empleo de suplementos en síndrome de deficiencia primaria de coenzima Q10, mientras en Reino Unido el National Institute for Health and Care Excellence (NICE) y el National Institute of Health (NIH) no recomiendan el empleo de estos suplementos para tratar mialgias asociadas al empleo de estatinas. Conclusiones: El conjunto de los estudios analizados no consiguió una evidencia unánime para poder recomendar este empleo de suplementos de coenzima Q10 de modo confiable. Se necesitan estudios mejor diseñados que aporten reproducibilidad y robustez a futuros ensayos clínicos.

APA, Harvard, Vancouver, ISO, and other styles

3

Azis, Samira, Jesús Rodríguez, Abraham Valladares, and Astrid Matheus. "Síndrome de Leigh: A propósito de un caso." Revista de Investigación Docencia y Extensión de la ULA (IDEULA), no. 1 (2021): 118–27. http://dx.doi.org/10.53766/ideula/2021.01.01.06.

Full text

Abstract:

El Síndrome de Leigh o Encefalopatía Necrotizante se caracteriza por una disfunción mitocondrial que lleva a un deterioro de la cadena respiratoria y por consiguiente de la fosforilación oxidativa; además posee una clínica inespecífica y es considerada un padecimiento poco frecuente en edades pediátricas. Se presenta el caso de paciente de 3 años de edad, con crisis convulsivas a los 5 meses de edad a quien se realizó tomografía axial computarizada donde se evidencia hipointensidad en ambos núcleos putaminales, se realizan estudios genéticos que resultan negativos y electroencefalograma donde se evidencia leve desorganización foco de onda aguda en área centro parietal derecha. Actualmente en tratamiento con L-carnitina, coenzima Q10, complejo B y Omega 3, logrando mejoría en el paciente.

APA, Harvard, Vancouver, ISO, and other styles

4

Ferreira Alfaya, Francisco Javier. "Controversias en la indicación de suplementos de coenzima Q10 para mitigar las mialgias asociadas a estatinas." Farmacéuticos Comunitarios 13, no. 1 (January 20, 2021): 5–6. http://dx.doi.org/10.33620/fc.2173-9218.(2021/vol13).001.02.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Da Silva, Thaíssa Augusto, Lara Gabriela de Araújo Cerqueira, Vitória Fernandes Freire De Melo, Thais Costa Machado Florence, Lana Mércia Santiago De Souza, Carine de Oliveira Sousa Bordallo, Joselita Moura Sacramento, and Edilene Maria Queiroz Araújo. "Suplementação de coenzima Q10 e redução dos efeitos colaterais da terapêutica com estatinas: uma revisão sistemática / Coenzyme Q10 supplementation and reduction of side effects of statin therapy: a systematic review." Brazilian Journal of Development 7, no. 8 (August 27, 2021): 84648–72. http://dx.doi.org/10.34117/bjdv7n8-600.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gonçalves, Lucas Cândido, Marcos de Oliveira Cunha, Gabriel de Oliveira Barbosa, Thiago Alves Digues, Raphael Ladislau de Alcantara, Xisto Sena Passos, Milton Camplesi Junior, Fábio Silvestre Ataídes, Arisneide Kasue Ikeda Rede, and Antonio Márcio Teodoro Cordeiro Silva. "Comparação nutricional e enzimática entre indivíduos saudáveis e fenilcetonúricos: revisão sistemática e metanálise." Revista Eletrônica Acervo Saúde, no. 41 (February 28, 2020): e2738. http://dx.doi.org/10.25248/reas.e2738.2020.

Full text

Abstract:

Objetivo: Este estudo objetivou avaliar as diferenças das médias de selênio, coenzima Q10 (CoQ10), status total antioxidante (STA), L-carnitina e glutationa peroxidase (GPx), comparando portadores de fenilcetonúria a indivíduos saudáveis, por meio de uma revisão sistemática e metanálise. Métodos: Para tal pesquisa foram selecionados 24 artigos, nas bases de dados PubMed e LILACS, 15 contribuíram com dados para as análises estatísticas, realizadas com o auxílio do software BioEstat® 5.3. Resultados: Todos os resultados referentes às concentrações séricas, demonstraram redução em fenilcetonúricos quando comparados com indivíduos saudáveis: selênio de 0,5 vez menor; CoQ10 com média de 0,08 vez menor; STA com média das diferenças de 0,15 vez menor; L-carnitina livre com média igual 7,8 vezes menor e GPx com concentração 1 vez menor. Em todas as médias a significância foi evidente, com p<0,0001. Considerações finais: É explícito a necessidade de uma suplementação nutricional, como tratamento coadjuvante a dieta restritiva, com o objetivo de evitar danos às membranas celulares e ao material genético.

APA, Harvard, Vancouver, ISO, and other styles

7

Milanez, Laura Gava, Laura Gava Milanez, and Laura Gava Milanez. "SUPLEMENTAÇÃO NUTRICIONAL NA INFERTILIDADE FEMININA E MASCULINA." Inova Saúde 12, no. 1 (August 11, 2021): 30. http://dx.doi.org/10.18616/inova.v12i1.6297.

Full text

Abstract:

Este artigo, cujo tema é “Suplementação na fertilidade feminina e masculina”, tem como objetivo apresentar a suplementação e a adequação nutricional como uma forma terapêutica para a infertilidade tanto em homens e mulheres, a qual poderá estar aliada com outros tipos de tratamento, desde que acompanhado por profissional, aumentando a possibilidade de casais gerarem filhos. Para tanto, aplicou-se uma pesquisa teórica de natureza básica, com método dedutivo, desenvolvido a partir de artigos indexados em: Informação em Saúde da América Latina e Caribe (LILACS); Sistema Online de Busca e Análise de Literatura Médica (MEDLINE) e Scientific Electronic Library Online (SciELO), entre outras. A pesquisa possibilitou concluir que os suplementos podem ter efeitos favoráveis na fertilidade feminina e masculina, através de uma variedade de mecanismos. Combinações de nutrientes como Coenzima Q10; o Ácido Lipoico; a Vitamina C; a Vitamina E; a L Carnitina e L Acetil Carnitina; o Omega 3; o Selênio e o Zinco, pode potencializar o processo de reprodução humana.

APA, Harvard, Vancouver, ISO, and other styles

8

Santos, Jefferson Jovelino Amaral dos, Ana Paula Tardivo, Thaís Cristina Coelho de Ornelas Salazar, and Victor Nascimento dos Santos. "Suplementação nutracêutica e fitoterápica no tratamento da fibromialgia: revisão de literatura." Research, Society and Development 10, no. 14 (October 31, 2021): e228101412381. http://dx.doi.org/10.33448/rsd-v10i14.12381.

Full text

Abstract:

A Fibromialgia (FB) é uma doença multifatorial que atinge uma grande parcela da população e ainda tem o seu diagnóstico como motivo de controvérsia. É caracterizada pela dor crônica em múltiplos pontos do corpo. O presente artigo teve como objetivo identificar ativos nutracêuticos que pudessem contribuir ao tratamento da FB nos seus múltiplos aspectos e assim, melhorar a qualidade de vida de seus portadores. O levantamento bibliográfico delimitou-se na busca de artigos em português e inglês nas bases de dados PubMed, SciELO e LILAC, publicados no período de janeiro de 2015 a março de 2020. Os princípios ativos mais encontrados no tratamento da FB foram a coenzima Q10, 25-hidroxivitamina D, probióticos (Lactobacillus Rhamnosus, Casei, Acidophilus e Bifidobacterium Bifidus) e fitoterápicos como gengibre, acerola, Spiraea Ulmari, passiflora, Elymus repens, em associação com outros produtos, o Crocus Sativus (açafrão) além do Ganoderma lucidum que é um tipo de cogumelo. É de fundamental importância a compreensão de como os suplementos podem auxiliar no tratamento da FB promovendo uma terapêutica mais natural, menos dispendiosa e com menos efeitos colaterais para os seus portadores.

APA, Harvard, Vancouver, ISO, and other styles

9

Silva, Jaqueline dos Santos, Thedemur Fortunato Soares de Oliveira, Maria Betânia Melo de Oliveira, Sivoneide Maria da Silva, Caio Rodrigo Dias de Assis, Hévellin Talita Sousa Lins, Renata Pereira Lima da Silva, et al. "Importância da suplementação com coenzima Q10 no combate aos radicais livres obtidos na atividade física de alta intensidade: uma revisão de literatura." Research, Society and Development 10, no. 15 (November 23, 2021): e453101523056. http://dx.doi.org/10.33448/rsd-v10i15.23056.

Full text

Abstract:

Introdução: A atividade física com a devida moderação traz benefícios para nossa saúde. No entanto, quando em excesso provoca um desgaste físico causando vários danos à saúde como lesão muscular, formação de radicais livres, estresse oxidativo e doenças degenerativas. A Coenzima Q10 (CoQ10) é uma benzoquinona essencial a vida, e está presente em todas as células do organismo humano, sendo conhecida pelo seu papel antioxidante, o presente estudo teve como objetivo identificar a relação da suplementação da CoQ10 após intensa atividade física de diferentes modalidades esportivas. Metodologia: Foi realizado um estudo de revisão da literatura em português, inglês e espanhol nas bases eletrônicas Periódicos CAPES, Pubmed, Scientific Eletronic Library On-line (SCIELO) e Scholar Google (Google Acadêmico). Foram selecionados aqueles que atendiam aos critérios de inclusão, como critério de inclusão, os artigos deveriam abordar assuntos relacionados aos descritores já citadas. Resultado: Exercícios físicos que ultrapassam o limite fisiológico, overtraining, tendem a promover um aumento na produção de radicais livres conhecidos como Espécies Reativas de Oxigênio (EROS) no organismo, os quais quando não neutralizados podem iniciar um processo deletério nas células e tecidos, ocasionando várias doenças degenerativas. A CoQ10 é uma substância produzida pelo nosso organismo, podendo também ser adquirida de fontes exógenas. Essa apresenta potente ação antioxidante e representa um componente-chave da cadeia respiratória mitocondrial gerando energia. Conclusão: De acordo com os trabalhos estudados, observou-se que a CoQ10 apresenta potente ação antioxidante no combatendo aos radicais livres, que são formados em praticantes de atividade física intensa.

APA, Harvard, Vancouver, ISO, and other styles

10

E Silva, Lívia Christine Santana, and Betânia de Jesus Silva A. Freitas. "Influência Dietética e Nutricional na Migrânea." Journal of Health Sciences 18, no. 1 (March 4, 2016): 64. http://dx.doi.org/10.17921/2447-8938.2016v18n1p64-70.

Full text

Abstract:

<p>A migrânea é um tipo de cefaleia altamente incapacitante, mais prevalente no sexo feminino e apresenta vários gatilhos dietéticos possíveis. A literatura traz alimentos, bebidas e condimentos que podem desencadear ou agravar as crises de migrânea, por outro lado, alguns constituintes alimentares podem ser úteis no tratamento desta. Em relação ao estado nutricional, obesos e desnutridos apresentam crises de migrânea mais duradoras e frequentes que pessoas com peso adequado. O objetivo deste estudo foi relacionar fatores dietéticos e nutricionais com a migrânea. Para tanto, realizou-se uma revisão sistemática de literatura nas bases de dados Pubmed, Medline, SciELO e Google Acadêmico, além de livros técnicos sobre o tema. A identificação dos gatilhos alimentares revela-se uma das maneiras mais eficientes para a redução das crises de migrânea. Porém, tendo em vista que alguns alimentos saudáveis têm sido relatados como gatilhos desta comorbidade, desaconselha-se sua eliminação total da dieta. Além disso, a literatura também tem trazido diversos componentes nutricionais atuantes na prevenção da migrânea, tais como: lecitina, ácidos graxos ômega-3 e ômega-6, fenilalanina, taurina, metionina e isoflavona, algumas ervas (manjericão, melissa, gengibre, artemísia), riboflavina, coenzima Q10, magnésio, niacina, carnitina, ácido lipoico e cafeína. Reforça-se ainda a importância da manutenção de um estado nutricional adequado, pois a concentração de gordura abdominal e a desnutrição estão relacionadas a uma maior incapacidade decorrente da migrânea. </p>

APA, Harvard, Vancouver, ISO, and other styles

11

Fernández-Fernández, F. J., R. Sardina-Ferreiro, and E. Ameneiros-Lago. "Nutracéuticos (monacolina K, berberina y coenzima Q10) en pacientes con hipercolesterolemia moderada y un riesgo cardiovascular bajo-moderado. Potenciales beneficios de los tratamientos combinados." Medicina de Familia. SEMERGEN 49, no. 2 (March 2023): 101836. http://dx.doi.org/10.1016/j.semerg.2022.101836.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

López Granollers, Gemma, Rafael Lafuente Varea, Miguel A. Checa Vizcaíno, Ana Monqaut, and Mario Brassesco Macazzaga. "Efecto del tratamiento con vitaminas, L-carnitina y coenzima Q10 en el índice de vacuolización y la fragmentación espermática en pacientes de fecundación in vitro." Revista Internacional de Andrología 9, no. 4 (October 2011): 154–59. http://dx.doi.org/10.1016/s1698-031x(11)70033-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Mila, C., D. M. Podea, and R. M. Chenderes. "Mild Cognitive Impairment and Quality of Life." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)71096-x.

Full text

Abstract:

Objective:The aim of this study is to evaluate the influence of cognitive enhancers on quality of life to patients with MCI.Material and methods:The study comprises a number of 40 elderly patients diagnosed with mild cognitive impairment. These patients were divided in two groups:group A that comprises 20 patients diagnosed with mild cognitive impairment that were treated with piracetamum (daily dose: 1600mg),group B that comprises 20 patients diagnosed with mild cognitive impairment that were treated with antioxidants Coenzima Q10 (daily dose: 15mg).MMSE score between 28-21points is considered mild cognitive impairment. The inclusion criteria were:patients over 65 years,patients with mild cognitive impairment.The exclusion criteria were:patients with mild cognitive impairment due to major depressive disorder and schizophrenia,patients with moderate and severe cognitive impairment.The patients were evaluated with MMSE (Mini Mental State Evaluation) and GAF (Global Assessment of Functioning Scale) at the inclusion and after 6 months of treatment.Results:The average of MMSE scores in group A was 25.9 and for group B 25.5. The patients treated with nootropics have had a better outcome, cognitive performance improving with 2,6 points for group A and with 1,8 points for group B. Improvement of cognitive performance improve the quality of life of this patients, the GAF scores improving from 45.4 points to 67.3 in group A and from 44.8 points to 55.3 in group B.Conclusions:The patients treated with nootopics have had a better outcome regarding cognitive functions and quality of life also. Improvement of cognitive performance improve the quality of life.

APA, Harvard, Vancouver, ISO, and other styles

14

Araújo, Francisco Emanoel Alves de, João Matheus Caé da Rocha, Bruna Jéssica Dantas de Lucena, Sarah Vitória Gomes de Sousa, Maria Raquel Araújo de Sousa, Lucas Emmanuel Rocha de Moura Marques, João Lindemberg Bandeira de Lima, Kellyson Lopes da Silva Macedo, and Salvador Viana Gomes Junior. "Avaliação da administração de coenzima Q10 na atenuação de respostas oxidativas da agregação β-Amiloide em modelos de doença de Alzheimer: Uma revisão sistemática de literatura." Research, Society and Development 10, no. 2 (February 21, 2021): e41210212751. http://dx.doi.org/10.33448/rsd-v10i2.12751.

Full text

Abstract:

O objetivo deste estudo foi avaliar os efeitos da administração de CoQ10 na atenuação de respostas oxidativas por agregação β-Amiloide em modelos de doença de Alzheimer. O presente trabalho trata-se de uma revisão sistemática da literatura, constituída de etapas estabelecidas por estratégias de busca, identificação, seleção e elegibilidade de estudos. A CoQ10 ou ubi-quinona e ubidecarenona, é uma pró-vitamina sintetizada de forma endógena, esta tem sido utilizada em ensaios clínicos para avaliar seu potencial de neuroproteção e antioxidação. Os achados mostraram que a CoQ10 apresenta efeitos antioxidantes e de diminuição da deposição intracelular do composto beta-amilóide, exercendo o alívio oxidativo e efeito antiapoptótico. A administração de CoQ10 demonstrou resultados significativos na atenuação de respostas oxidativas de agregação β-Amiloide em modelos da DA.

APA, Harvard, Vancouver, ISO, and other styles

15

Sarifuddin, Nurhidayah, Widji Soerarti, and Noorma Rosita. "Preparation and Characteristics of NLC Coenzym Q10 with A Combination of Hyaluronic Acid." Health Notions 3, no. 1 (January 31, 2019): 32–36. http://dx.doi.org/10.33846/hn.v3i1.250.

Full text

Abstract:

Coenzyme Q10, often also known as ubiquinone, coenzyme Q10 or Q10, is soluble in lipids and is naturally present in plants, animals and in mitochondria. Coenzyme Q10 functions as an antioxidant that can protect the body from damage caused by free radicals. Hyaluronic acid is known as a hydrophilic polymer derived from polysaccharides which has the ability to increase percutaneous penetration by changing the composition of tightly arranged stratum corneum cells to increase the permeability of the skin. Nanostructured Lipid Carrier is a modification of the SLN system, consisting of a mixture of solid and liquid lipids (oil), stabilized by aqueous surfactant solution, is one method to increase drug penetration through the stratum corneum because it has several advantages. The purpose of this study was to see the effect of adding hyaluronic acid to the characteristics of the Nanostructure Lipid Carrier (NLC) as anti aging. Examination of characteristics including organoletis, pH, particle size and polidispersity index was carried out. The results of organoleptic NLC coenzym Q10-HA examination obtained dark orange color, liquid consistency, lipid efficacy odor and soft texture. The pH measurement results of the preparation ranged from 5.05-5.23. The results of the particle size examination ranged from 267-128 nm and the particle size distribution ranged between 0.308-0.200 Keywords: Coenzym Q10, Hyaluronic acid , NLC

APA, Harvard, Vancouver, ISO, and other styles

16

Sugano, Naoyuki. "Coenzyme Q10." Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology) 59, no. 2 (2017): 63–67. http://dx.doi.org/10.2329/perio.59.63.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

ÖZTURAN ŞİRİN, Ayçıl, and Yasemin AKDEVELİOĞLU. "Erkek İnfertilitesinde Koenzim Q10." Turkiye Klinikleri Journal of Health Sciences 6, no. 1 (2021): 139–47. http://dx.doi.org/10.5336/healthsci.2020-75062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lomangino, Kevin. "Coenzyme Q10." Clinical Nutrition INSIGHT 33, no. 8 (August 2007): 5–6. http://dx.doi.org/10.1097/01.nmd.0000284437.43690.8f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Hume, Anne L. "Coenzyme Q10." Pharmacy Today 25, no. 2 (February 2019): 16. http://dx.doi.org/10.1016/j.ptdy.2019.01.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Molyneux, Sarah L., Christopher M. Florkowski, Peter M. George, Anna P. Pilbrow, Christopher M. Frampton, Michael Lever, and A. Mark Richards. "Coenzyme Q10." Journal of the American College of Cardiology 52, no. 18 (October 2008): 1435–41. http://dx.doi.org/10.1016/j.jacc.2008.07.044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Moyer, Gretchen H., and Esther Y. Dell. "Coenzyme Q10." Health Care on the Internet 1, no. 4 (September 1997): 75–80. http://dx.doi.org/10.1300/j138v01n04_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Pepping, Joseph. "Coenzyme Q10." American Journal of Health-System Pharmacy 56, no. 6 (March 15, 1999): 519–21. http://dx.doi.org/10.1093/ajhp/56.6.519.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Ross, Stephanie Maxine. "Coenzyme Q10." Holistic Nursing Practice 21, no. 4 (July 2007): 213–14. http://dx.doi.org/10.1097/01.hnp.0000280934.42710.e7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Petrangolini, Giovanna, Massimo Ronchi, Elisabetta Frattini, Eric De Combarieu, Pietro Allegrini, and Antonella Riva. "A New Food-grade Coenzyme Q10 Formulation Improves Bioavailability: Single and Repeated Pharmacokinetic Studies in Healthy Volunteers." Current Drug Delivery 16, no. 8 (October 9, 2019): 759–67. http://dx.doi.org/10.2174/1567201816666190902123147.

Full text

Abstract:

Background: Coenzyme Q10 is a fundamental endogenous factor involved in cell energy production that shows protective properties in oxidative stress, mainly in skeletal and heart muscle. Coenzyme Q10 supplementation appears to benefit athletes in strenuous training and in the elderly, demonstrating ant-inflammatory properties by reducing inflammatory cytokines. Improved absorption of coenzyme Q10 via a new delivery system would represent an important step forward in the use of coenzyme Q10 as a dietary supplement. Objective: The aim of the study was to evaluate the solubility and oral absorption in human healthy volunteers of a new food grade coenzyme Q10 phytosome formulation. Methods: Solubility studies were performed in vitro in simulated gastrointestinal fluids; human studies were conducted in healthy volunteers to evaluate oral absorption in a Single dose study, in comparison with the coenzyme Q10 capsules, and in a repeated study at two increasing doses. Results: The highest solubility shown by coenzyme Q10 phytosome in simulated intestinal fluids results in an improvement in oral absorption of coenzyme Q10 in healthy volunteers, three times more than the coenzyme Q10 according to AUC (area under the time/concentration curve) values. When two increasing doses (one and two capsules) were administered to healthy volunteers within a two-week schedule, the plasmatic levels of coenzyme Q10 resulted in 0.864±0.200 μg/ml (Mean±S.D.+41%) and 1.321±0.400 μg/ml (+116%), respectively versus baseline (0.614±0.120 μg/ml one capsule, 0.614±0.160 μg/ml two capsules). This detected dose-related bioavailability of coenzyme Q10 phytosome was even observed with no alterations in vital signs, neither in the physical examination nor in ECG, and no changes of clinical and biochemical parameters were observed. Conclusion: These findings, taken together, support the safety profile and significantly improved coenzyme Q10 oral absorption in humans with this new phytosome delivery formulation.

APA, Harvard, Vancouver, ISO, and other styles

25

Li, Qian-wei, Qin Yang, Hong-Yang Liu, Yu-ling Wu, Yu-Hua Hao, and Xiao-Qing Zhang. "Protective Role of Coenzyme Q10 in Acute Sepsis-Induced Liver Injury in BALB/c Mice." BioMed Research International 2020 (December 18, 2020): 1–9. http://dx.doi.org/10.1155/2020/7598375.

Full text

Abstract:

Sepsis increases the risk of the liver injury development. According to the research works, coenzyme Q10 exhibits hepatoprotective properties in vivo as well as in vitro. Current work aimed at investigating the protective impacts of coenzyme Q10 against liver injury in septic BALB/c mice. The male BALB/c mice were randomly segregated into 4 groups: the control group, the coenzyme Q10 treatment group, the puncture and cecal ligation group, and the coenzyme Q10+cecal ligation and puncture group. Cecal ligation and puncture was conducted after gavagaging the mice with coenzyme Q10 during two weeks. Following 48 h postcecal ligation and puncture, we estimated hepatic biochemical parameters and histopathological changes in hepatic tissue. We evaluated the expression of factors associated with autophagy, pyroptosis, and inflammation. Findings indicated that coenzyme Q10 decreased the plasma levels in alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase in the cecal ligation and puncture group. Coenzyme Q10 significantly inhibited the elevation of sequestosome-1, interleukin-1β, oligomerization domain-like receptor 3 and nucleotide-binding, interleukin-6, and tumor necrosis factor-α expression levels; coenzyme Q10 also increased beclin 1 levels. Coenzyme Q10 might be a significant agent in the treatment of liver injury induced by sepsis.

APA, Harvard, Vancouver, ISO, and other styles

26

Streacker, Caitlin, and Brian D. Whitaker. "Coenzyme Q10 Supplementation Effects on In Vitro Maturation, Fertilization, and Early Embryonic Development in Pigs." Ohio Journal of Science 119, no. 2 (April 30, 2019): 2. http://dx.doi.org/10.18061/ojs.v119i2.6366.

Full text

Abstract:

The objective of this study was to determine the reduction of polyspermic penetration, and increase of mitochondrial activity, in early pig embryonic development by supplementing different concentrations of coenzyme Q10 during oocyte maturation. Oocytes (n = 1,100) were supplemented during the last 24 h of maturation with 0 (control), 10, 50, or 100 μM of coenzyme Q10. After in vitro fertilization (IVF), embryos were evaluated for fertilization kinetics (penetration, polyspermic penetration, male pronuclear formation), and subsequent embryonic development and mitochondrial activity. Supplementation of 100 μM coenzyme Q10 was detrimental to the oocytes, as they had significantly lower (p < 0.05) fertilization kinetic and early embryonic development rates to the other treatment groups. There were no differences in fertilization kinetic and early embryonic development rates between the 0, 10 and 50 μM coenzyme Q10 treatment groups. Oocytes, matured in medium supplemented with 50 μM coenzyme Q10, ultimately developed into embryos with a significantly greater (p < 0.05) presence of intact mitochondrial membranes (observed at both 48 and 144 h post-IVF) compared to oocytes not supplemented with coenzyme Q10. In summary, supplementation of 100 μM coenzyme Q10 during oocyte maturation is detrimental, yet supplementation of 50 μM coenzyme Q10 leads to a higher occurrence of intact mitochondrial membranes in the in vitro produced pig embryos.

APA, Harvard, Vancouver, ISO, and other styles

27

Zozina, V. I., E. S. Melnikov, L. M. Krasnykh, O. A. Goroshko, and V. G. Kukes. "THE IMPACT OF CARDIOVASCULAR AND BRONCHOPULMONARY DISEASES ON COENZYME Q10 PLASMA CONCENTRATION." Sechenov Medical Journal 10, no. 1 (March 30, 2019): 16–21. http://dx.doi.org/10.47093/22187332.2019.1.16-21.

Full text

Abstract:

Introduction. Coenzyme Q10 plays an important role in the human body. Its main function is not only the transfer of electrons in the mitochondrial respiratory chain for the ATP synthesis, but it is also one of the most powerful antioxidants in the body.The aim of research is to monitor the relationship between cardiovascular and pulmonary diseases, and the concentration of coenzyme Q10 in the blood plasma.Materials and methods. Coenzyme Q10 was determined using high performance liquid chromatography with mass spectrometric detection.Results and discussion. During the study, it was found that the concentration of coenzyme Q10 in plasma is aﬀected not only by the main diseases, but also by comorbidities, as well as by the therapy. A sharp decrease in plasma coenzyme Q10 concentration was noted in patients with cardiovascular pathologies, especially in those with concomitant endocrine diseases. Also, it was recorded a decrease in the concentration of coenzyme Q10 in the plasma of patients with pneumonia. Conclusion. During the experiment, the coenzyme Q10 concentration was found to be dependent on cardiovascular and pulmonary diseases.

APA, Harvard, Vancouver, ISO, and other styles

28

Montini, Giovanni, Cristina Malaventura, and Leonardo Salviati. "Early Coenzyme Q10 Supplementation in Primary Coenzyme Q10 Deficiency." New England Journal of Medicine 358, no. 26 (June 26, 2008): 2849–50. http://dx.doi.org/10.1056/nejmc0800582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Chang, Po-Sheng, Chi-Hua Yen, Yu-Yun Huang, Ching-Ju Chiu, and Ping-Ting Lin. "Associations between Coenzyme Q10 Status, Oxidative Stress, and Muscle Strength and Endurance in Patients with Osteoarthritis." Antioxidants 9, no. 12 (December 14, 2020): 1275. http://dx.doi.org/10.3390/antiox9121275.

Full text

Abstract:

Osteoarthritis (OA) causes oxidative stress. Coenzyme Q10 is an antioxidant that participates in energy production in the human body. The purpose of this study was to investigate the relationships among coenzyme Q10 status, oxidative stress, antioxidant capacity, and muscle function in patients with OA. This case-control study recruited 100 patients with OA and 100 without OA. The coenzyme Q10 status, oxidative stress, antioxidant capacity, muscle mass (by dual-energy X-ray absorptiometry), muscle strength (hand-grip and leg-back strength), and muscle endurance (dumbbell curls, gait speed, chair-stand test, and short physical performance battery) were measured. The results showed that both OA and elderly subjects had a low coenzyme Q10 status (<0.5 μM). Oxidative stress was significantly negatively correlated with muscle function (protein carbonyl, p < 0.05). Coenzyme Q10 level was positively associated with antioxidant capacity, muscle mass, muscle strength and muscle endurance in patients with OA (p < 0.05). Since OA is an age-related disease, coenzyme Q10 may be consumed by oxidative stress and thereby affect muscle function. Raising coenzyme Q10 in patients with OA could be suggested, which may benefit their antioxidant capacity and muscle function.

APA, Harvard, Vancouver, ISO, and other styles

30

Mantle, David, and Iain P. Hargreaves. "Coenzyme Q10 supplementation in non-alcoholic fatty liver disease: an overview." Journal of Prescribing Practice 2, no. 4 (April 2, 2020): 200–204. http://dx.doi.org/10.12968/jprp.2020.2.4.200.

Full text

Abstract:

Non-alcoholic fatty liver disease is the most common liver disorder in the UK, for which little effective conventional treatment is available. Mitochondrial dysfunction, oxidative stress and inflammation have been implicated in the pathogenesis of non-alcoholic fatty liver disease. This article focuses on the role of the vitamin-like substance coenzyme Q10 in non-alcoholic fatty liver disease, since coenzyme Q10 plays a key role in mitochondrial function, as well as having antioxidant and anti-inflammatory action. Coenzyme Q10 levels are depleted in non-alcoholic fatty liver disease, and studies in animal models and human subjects have indicated that supplementation with coenzyme Q10 can significantly reduce oxidative stress and the inflammation characteristic of non-alcoholic fatty liver disease. In addition, Non-alcoholic fatty liver disease patients are at increased risk of developing heart failure, and supplementary coenzyme Q10 may help to reduce this risk. Supplementary coenzyme Q10 is generally well tolerated, with no significant adverse effects reported in long-term use.

APA, Harvard, Vancouver, ISO, and other styles

31

Wear, Darcy, Caleb Vegh, Jagdeep K. Sandhu, Marianna Sikorska, Jerome Cohen, and Siyaram Pandey. "Ubisol-Q10, a Nanomicellar and Water-Dispersible Formulation of Coenzyme-Q10 as a Potential Treatment for Alzheimer’s and Parkinson’s Disease." Antioxidants 10, no. 5 (May 11, 2021): 764. http://dx.doi.org/10.3390/antiox10050764.

Full text

Abstract:

The world continues a desperate search for therapies that could bring hope and relief to millions suffering from progressive neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD). With oxidative stress thought to be a core stressor, interests have long been focused on applying redox therapies including coenzyme-Q10. Therapeutic use has failed to show efficacy in human clinical trials due to poor bioavailability of this lipophilic compound. A nanomicellar, water-dispersible formulation of coenzyme-Q10, Ubisol-Q10, has been developed by combining coenzyme-Q10 with an amphiphilic, self-emulsifying molecule of polyoxyethanyl α-tocopheryl sebacate (derivatized vitamin E). This discovery made possible, for the first time, a proper assessment of the true therapeutic value of coenzyme-Q10. Micromolar concentrations of Ubisol-Q10 show unprecedented neuroprotection against neurotoxin exposure in in vitro and in vivo models of neurodegeneration and was extremely effective when delivered either prior to, at the time of, and most significantly, post-neurotoxin exposure. These findings indicate a possible way forward for clinical development due to effective doses well within Federal Drug Administration guidelines. Ubisol-Q10 is a potent mobilizer of astroglia, antioxidant, senescence preventer, autophagy activator, anti-inflammatory, and mitochondrial stabilizer. Here we summarize the work with oil-soluble coenzyme-Q10, its limitations, and focus mainly on efficacy of water-soluble coenzyme-Q10 in neurodegeneration.

APA, Harvard, Vancouver, ISO, and other styles

32

Singh, Ram, Jan Fedacko, Viliam Mojto, and Dominik Pella. "Coenzyme Q10 Modulates Remodeling Possibly by Decreasing Angiotensin-Converting Enzyme in Patients with Acute Coronary Syndrome." Antioxidants 7, no. 8 (July 25, 2018): 99. http://dx.doi.org/10.3390/antiox7080099.

Full text

Abstract:

The study aims to examine the effects of coenzyme Q10, (a bioenergetic antioxidant), on the indexes of left ventricular remodeling, oxidative damage, and angiotensin-converting enzyme (ACE) level after acute myocardial infarction (AMI) with left ventricular dysfunction. In a double blind, randomized, placebo-controlled, parallel group study (a retrospective analysis of an earlier trial) in 55 patients with left ventricular ejection fraction <50% after AMI, the effects of coenzyme Q10 (120 mg/day) or placebo were studied for 24 weeks. Two-dimensional echocardiography was performed at discharge, (approximately 5–10 days after admission) and at 6 months after AMI. The results revealed that wall thickness opposite the site of infarction decreased from (mean ± standard deviation (SD)) 12.2 ± 2.0 mm to 10.0 ± 1.8 mm with coenzyme Q10 compared with 12.8 ± 2.2 mm to 13.3 ± 2.3 mm with placebo (p < 0.01). Left ventricular mass changed from 236 ± 72 g to 213 ± 61 g with coenzyme Q10 compared with 230 ± 77 g to 255 ± 86 g with placebo (p < 0.01). Treatment with coenzyme Q10 also prevented alteration of sphericity index which is a ratio of the long and short axis of the left ventricle (which changed from 1.61 ± 0.28 to 1.63 ± 0.30 with coenzyme Q10 compared with 1.61 ± 0.32 to 1.41 ± 0.31 with placebo (p < 0.05)). Coenzyme Q10 also prevented alteration of the wall thickening abnormality at the infarct site, which changed from 9.4 ± 3.0 cm2 to 9.1 ± 2.8 cm2 compared with 10.1 ± 3.1 to 13.7 ± 4.2 cm2 with placebo (p < 0.05). End diastolic and systolic volumes also showed significant reduction with coenzyme Q10 compared to placebo. The serum level of ACE showed significant decline in the coenzyme Q10 group compared to the control group. Treatment with coenzyme Q10 early after AMI causes attenuation of left ventricular remodeling and decreases the serum ACE level in patients with left ventricular dysfunction.

APA, Harvard, Vancouver, ISO, and other styles

33

Filipiak, Krzysztof J., Stanisław Surma, Monika Romańczyk, and Bogusław Okopień. "Heart Failure—Do We Need New Drugs or Have Them Already? A Case of Coenzyme Q10." Journal of Cardiovascular Development and Disease 9, no. 5 (May 16, 2022): 161. http://dx.doi.org/10.3390/jcdd9050161.

Full text

Abstract:

Heart failure (HF) is a global epidemic that contributes to the deterioration of quality of life and its shortening in 1–3% of adult people in the world. Pharmacotherapy of HF should rely on highly effective drugs that improve prognosis and prolong life. Currently, the ESC guidelines from 2021 indicate that ACEI, ARNI, BB, and SGLT2 inhibitors are the first-line drugs in HF. It is also worth remembering that the use of coenzyme Q10 brought many benefits in patients with HF. Coenzyme Q10 is a very important compound that performs many functions in the human body. The most important function of coenzyme Q10 is participation in the production of energy in the mitochondria, which determines the proper functioning of all cells, tissues, and organs. The highest concentration of coenzyme Q10 is found in the tissue of the heart muscle. As the body ages, the concentration of coenzyme Q10 in the tissue of the heart muscle decreases, which makes it more susceptible to damage by free radicals. It has been shown that in patients with HF, the aggravation of disease symptoms is inversely related to the concentration of coenzyme Q10. Importantly, the concentration of coenzyme Q10 in patients with HF was an important predictor of the risk of death. Long-term coenzyme Q10 supplementation at a dose of 300 mg/day (Q-SYMBIO study) has been shown to significantly improve heart function and prognosis in patients with HF. This article summarizes the latest and most important data on CoQ10 in pathogenesis.

APA, Harvard, Vancouver, ISO, and other styles

34

Aryani, Ni Luh Dewi, Siswandono Siswandono, Wdji Soeratri, Dian Yulyandani Putri, and Pingky Dwi Puspitasarini. "Development, characterization in vitro and in silico of coenzyme Q10 loaded myristic acid with different liquid lipids nanostructured lipid carriers." Journal of Pharmacy & Pharmacognosy Research 9, no. 5 (September 1, 2021): 573–83. http://dx.doi.org/10.56499/jppres21.1038_9.5.573.

Full text

Abstract:

Context: Nanostructured lipid carriers can enhance skin penetration of active substances. Coenzyme Q10 is a lipophilic antioxidant, that has poor skin penetration. This limitation is overcome by nanostructured lipid carriers. Aims: To developed coenzyme Q10 nanostructured lipid carriers using myristic acid with various liquid lipids as lipid matrix by in vitro studies and in silico approach for explaining the interaction of coenzyme Q10-lipid at the molecular level. Methods: The coenzyme Q10 nanostructured lipid carriers were prepared using myristic acid as solid lipid with oleic acid, isopropyl myristate, and isopropyl palmitate as liquid lipids using the high shear homogenization method. Then, they were evaluated in physicochemical characteristics by dynamic light scattering, differential scanning calorimetry, Fourier transforms infrared, scanning electron microscopy, spectrophotometry ultraviolet-visible, and pH meter. Furthermore, the in silico studies were conducted using AutoDock 4.2. Results: The coenzyme Q10 nanostructured lipid carriers using myristic acid-oleic acid, myristic acid-isopropyl myristate, and myristic acid-isopropyl palmitate as lipid matrix had the mean particle size, polydispersity index, entrapment efficiency, drug loading, and pH value were less than 300 nm, less than 0.3, more than 80%, about 10%, and about 5.0, respectively. Moreover, molecular docking of coenzyme Q10 and lipid showed hydrogen and hydrophobic bonds. These results supported differential scanning calorimetry and Fourier transforms infrared results. Conclusions: The coenzyme Q10 nanostructured lipid carriers were successfully prepared using myristic acid-oleic acid, myristic acid-isopropyl myristate, and myristic acid-isopropyl palmitate as lipid matrix as well as in silico study could be used for explaining of coenzyme Q10-lipid interaction.

APA, Harvard, Vancouver, ISO, and other styles

35

Kostrzewska, Paulina, Amanda Mandera, Krystian Nagi, Anna Pawlikowska, and Ewa Szuster. "Coenzyme Q10 – a literature review on supplementation in chronic disorders and the anti-aging process." Pediatria i Medycyna Rodzinna 18, no. 2 (September 16, 2022): 134–38. http://dx.doi.org/10.15557/pimr.2022.0019.

Full text

Abstract:

Introduction: The continuous growth and aging of the population poses enormous challenges in maintaining the health of the entire world’s population, which is forecasted to exceed 9 billion by 2050. Diseases of the XXI century can be prevented by reducing risk factors and appropriate prophylaxis, which also includes supplementation. Aim: The aim of the study was to summarise data on the effects of coenzyme Q10 on the course of chronic diseases and the aging process. Materials and methods: PubMed and Google Scholar databases were searched. Most of the articles published after 2012 were reviewed. Brief description of the state of knowledge: Decreased levels of coenzyme Q10 and increased levels of oxidative stress have been found in the course of multiple chronic diseases. It seems logical that coenzyme Q10 supplementation improves mitochondrial function and provides antioxidant protection to organs and tissues affected by various pathophysiological conditions. In addition to significantly improving cardiovascular and neurological functions, coenzyme Q10 has also found a wide application in delaying skin aging processes. Conclusions: Coenzyme Q10 is the third most commonly used dietary supplement in the world. The efficacy of coenzyme Q10 in selected groups of patients has been confirmed in clinical trials. More research and clinical trials are needed with more participants undergoing longer-term supplementation to assess the benefits of coenzyme Q10.

APA, Harvard, Vancouver, ISO, and other styles

36

Jahan, Sarwat, Sher Afghan Khan, Abdus Salam, Inayat Ur Rehman, Omer Farooq, and Arsalan Afridi. "Comparative Analysis of the Hepatoprotective Potential of Coenzyme Q10 as a Preventive and a Therapeutic Agent in Statin-Induced Hepatotoxicity." Molecular Medicine Communications 2, no. 01 (June 30, 2022): 21–30. http://dx.doi.org/10.55627/mmc.002.001.0025.

Full text

Abstract:

Statins induce hepatotoxicity via reduced levels of Coenzyme Q10, inflammation, and oxidative stress. Coenzyme Q10 is anti-apoptotic and possesses an antioxidative potential and hence has been studied for its hepatoprotective potential. However, owing to the differing mechanisms of prevention of damage and its reversal, we hypothesize that coenzyme Q10 will have varying efficacy as a protective versus a therapeutic approach. An experimental study of 3 weeks was conducted in the department of Pharmacology on a sample of 35 mice, randomly divided into 7 groups. Group 1 was used as a control. Group 2 received simvastatin 50mg/kg/day of simvastatin intraperitoneally (I/P). Group 3 received I/P 50mg/kg/day rosuvastatin. Group 4 received 50mg/kg/day of simvastatin+10mg/kg of coenzyme Q10. Group 5 received 50mg/kg/day of rosuvastatin+10mg/kg of coenzyme Q10 I/P. In group 6 simvastatin 50mg/kg & 7 rosuvastatin 50mg/kg was given for a week, and 10mg/kg of Coenzyme Q10 was started in the 2nd week and continued for 2 weeks. Hepatic damage was observed in groups 2,3,6 and 7 indicated by raised ALT levels of 320.4, 179.8, 301.4, and 186.8 and raised AST levels of 320, 196, 421.4, and 307.6. Bilirubin stayed within normal limits. Coenzyme Q10 prevents statin-induced liver damage but has no role as a therapeutic agent once the liver damage has already occurred.

APA, Harvard, Vancouver, ISO, and other styles

37

Wolters and Hahn. "Plasma Ubiquinone Status and Response to Six-Month Supplementation Combined with Multivitamins in Healthy Elderly Women – Results of a Randomized, Double-Blind, Placebo-Controlled Study." International Journal for Vitamin and Nutrition Research 73, no. 3 (May 1, 2003): 207–14. http://dx.doi.org/10.1024/0300-9831.73.3.207.

Full text

Abstract:

The aim of this study was to evaluate the serum coenzyme Q10 concentrations of healthy elderly women before and after supplementation with coenzyme Q10 combined with multivitamins, selenium, and magnesium. In a randomized double-blind design, 220 free-living women aged 60 years and older were included. Median serum coenzyme Q10 concentration at baseline was 0.99 mumol/L (5–95 percentiles: 0.54–1.68) and cholesterol adjusted concentration was 0.16 (5–95 percentiles: 0.09–0.26) mmol/mol cholesterol. No significant correlations were found between Q10 levels and body mass index (BMI) or age. Q10 concentrations were not significantly different between smoking and nonsmoking women, nor between women with statin therapy and without. Furthermore no differences were seen between hyperlipidemic and normolipidemic subjects. Cholesterol-adjusted Q10 levels were positively correlated to lipid-adjusted serum tocopherol levels and negatively associated to serum beta-carotene. No significant correlation existed between adjusted Q10 levels and plasma selenium. Results of the food diaries showed a significant but weak correlation to meat and meat products and to alcohol intake. At baseline, Q10 levels did not differ between supplemented and control group. After six months, adjusted serum concentrations of the supplemented and the control group were significantly increased by 106% and 31%, respectively. In the supplemented group the change was inversely associated with the baseline concentration. A six-month supplementation with coenzyme Q10, vitamins, and selenium raises the blood concentration of coenzyme Q10 even in relatively well-nourished elderly women.

APA, Harvard, Vancouver, ISO, and other styles

38

Lee, Bor-Jen, Yi-Chin Lin, Yi-Chia Huang, Ya-Wen Ko, Simon Hsia, and Ping-Ting Lin. "The Relationship between Coenzyme Q10, Oxidative Stress, and Antioxidant Enzymes Activities and Coronary Artery Disease." Scientific World Journal 2012 (2012): 1–8. http://dx.doi.org/10.1100/2012/792756.

Full text

Abstract:

A higher oxidative stress may contribute to the pathogenesis of coronary artery disease (CAD). The purpose of this study was to investigate the relationship between coenzyme Q10 concentration and lipid peroxidation, antioxidant enzymes activities and the risk of CAD. Patients who were identified by cardiac catheterization as having at least 50% stenosis of one major coronary artery were assigned to the case group (n=51). The control group (n=102) comprised healthy individuals with normal blood biochemical values. The plasma coenzyme Q10, malondialdehyde (MDA) and antioxidant enzymes activities (catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx)) were measured. Subjects with CAD had significant lower plasma coenzyme Q10, CAT and GPx activities and higher MDA and SOD levels compared to those of the control group. The plasma coenzyme Q10 was positively correlated with CAT and GPx activities and negatively correlated with MDA and SOD. However, the correlations were not significant after adjusting for the potential confounders of CAD with the exception of SOD. A higher level of plasma coenzyme Q10 (≥0.52 μmol/L) was significantly associated with reducing the risk of CAD. Our results support the potential cardioprotective impact of coenzyme Q10.

APA, Harvard, Vancouver, ISO, and other styles

39

Craciun, Veronica Isabela, Felicia Gabriela Gligor, Anca Maria Juncan, Luca Liviu Rus, and Claudiu Morgovan. "Ubidecarenone Quantification in Food Supplements A new HPLC method." Revista de Chimie 70, no. 10 (November 15, 2019): 3575–78. http://dx.doi.org/10.37358/rc.19.10.7599.

Full text

Abstract:

Coenzyme Q10 has a powerful antioxidant effect because it protects cells against free radicals and plays an important role in metabolism. Although controversial some preliminary evidence suggests that Coenzyme Q10 can help prevent or treat treatment of diseases of the cardiovascular and musculoskeletal systems and liver problems. Age increase and medical conditions are associated with lower Coenzyme Q10. There are evidences that diet supplementation with supplements containing Coenzyme Q10 may be beneficial. This paper aims to develop an HPLC method for identifying and dosing Ubidecarenone in food supplements. Using this technique, several supplements containing varying Ubidecarenone, ranging from 76 to 103% of the stated amount per dosage form were tested.

APA, Harvard, Vancouver, ISO, and other styles

40

Banihani, Saleem. "Effect of Coenzyme Q10 Supplementation on Testosterone." Biomolecules 8, no. 4 (December 13, 2018): 172. http://dx.doi.org/10.3390/biom8040172.

Full text

Abstract:

Enhancing testosterone production in males is a continuous research direction for many scientists in the field, due to its role as a principal sex hormone and as a crucial modulator of well-being and general health in humans. Since 1978, there have been more than 30 studies that have connected coenzyme Q10 and testosterone. Such a link is attributable to the vigorous biological role of coenzyme Q10 as a crucial member in the energy production route in humans and animals, which is thought to have a positive influence on testosterone production, and hence on infertility, particularly male infertility. However, this connection has not yet been deliberated. The present work systematically reviews and summarizes the influence of coenzyme Q10 supplementation on testosterone. To accomplish this purpose, the Scopus, PubMed, and Web of Science databases were searched using the keywords “coenzyme Q10” versus “testosterone” for English language papers from November 1978 through October 2018. Relevant articles were also discussed and included to address an integral discussion. In summary, to date the studies conducted on human males reveal insignificant effects of coenzyme Q10 supplementation on testosterone. Similarly, rather than the reproductive toxicity studies, the studies conducted on animals did not show any positive influence of coenzyme Q10 on testosterone. However, coenzyme Q10 supplementation was found to ameliorate the reduction in testosterone induced by chemical reproductive toxicants, mainly by neutralizing the damaging effect of the generated free radicals. However, collectively these findings require further confirmation by additional research studies.

APA, Harvard, Vancouver, ISO, and other styles

41

Putranti, Astridani Rizky, Esti Hendradi, and Riesta Primaharinastiti. "EFFECTIVITY AND PHYSICOCHEMICAL STABILITY OF NANOSTRUCTURED LIPID CARRIER COENZYME Q10 IN DIFFERENT RATIO of LIPID ALFA CETYL PALMITATE AND ALPHA TOCOPHERYL ACETATE AS CARRIER." Asian Journal of Pharmaceutical and Clinical Research 10, no. 2 (February 1, 2017): 146. http://dx.doi.org/10.22159/ajpcr.2017.v10i2.14835.

Full text

Abstract:

Objective: The aim of this study was to investigate physical characteristics of nanostructured lipid carriers (NLCs) mixture of alpha tocopheryl acetate, cetyl palmitate, Tween 80 and propylene glycol using high shear homogenization technique on NLC preparation to predict the optimum ratio of alpha tocopheryl acetate-cetyl palmitate to produce good characteristics of NLC loaded coenzyme, higher % EE, good penetration, controlled release, and stable.Methods: Lipid characterizations were conducted by diffraction scanning calorimetry, X-ray diffraction, and Fourier transforms infrared spectrophotometry. Coenzyme Q10 concentration was measured by spectrophotometer at 275 nm. NLC characteristics based on their morphology was determined using transmission electron microscope, particle size, and its polydispersity index which were measured with Delsa Nano™ particle size analyzer. Percentage of coenzyme Q10 entrapped in NLC was determined by dialysis bag method. Coenzyme Q10 release profile was measured using with Franz cell for 12 hrs. The penetration depth of NLC coenzyme Q10 in abdominal skin of Wistar rat was determined with fluorescence microscopy using rhodamine B as marker. NLC physical stability based on minimum of particle size variation, pH and viscosity during 90 days storage.Results: The result showed that formula with ratio of cetyl palmitate-alpha tocopheryl acetate 70:30 (% w/w) produce good characteristics of NLCloaded coenzyme, higher % EE, good penetration, controlled release, and stable in 90 days storage.Conclusion: The coenzyme Q10 NLC system with cetyl palmitate and alpha tocopherol acetate as lipid matrixare characterized by small particle size, low crystallinity, spherical morphology of particle and high coenzyme Q10 entrapment efficiency. Crystal modification led to the formation of a more amorphous thereby increasing the drug entrapmentKeywords: Coenzyme Q10, Nanostructured lipid carrier, Cetyl palmitate, Alpha tocopheryl acetate, High shear homogenization.

APA, Harvard, Vancouver, ISO, and other styles

42

Hormozi, Maryam, Ramazan Mirzaei, Alireza Nakhaee, Abolfazl payandeh, Shahrokh Izadi, and Javid Dehghan Haghighi. "Effects of coenzyme Q10 supplementation on oxidative stress and antioxidant enzyme activity in glazers with occupational cadmium exposure: A randomized, double-blind, placebo-controlled crossover clinical trial." Toxicology and Industrial Health 35, no. 1 (November 19, 2018): 32–42. http://dx.doi.org/10.1177/0748233718809256.

Full text

Abstract:

Recently, there is a growing interest for the use of antioxidants as a preventive agent against cadmium (Cd) intoxication. The current study aimed to investigate the effects of dietary coenzyme Q10 supplementation on oxidative stress and antioxidant enzymes activity in Cd-exposed glazers. In a randomized, double-blind, placebo-controlled 2-month crossover clinical trial, coenzyme Q10 (60 mg twice daily) or placebo was administrated to 40 male glazers occupationally exposed to Cd. The subjects were randomly assigned to the placebo and coenzyme Q10 groups ( n = 20 in each group). Total antioxidant capacity (TAC), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) as well as malondialdehyde (MDA) in the serum of glazers were measured at baseline and at the end of both intervention phases. The primary outcomes were the changes in serum levels of MDA, TAC and the activities of SOD, CAT, and GPx during administration with coenzyme Q10 versus placebo. Compared with placebo, treatment to coenzyme Q10 was associated with a significant reduction in serum MDA levels ( p < 0.001) While, there was no significant effect on the serum TAC levels ( p = 0.096). Also, the activity antioxidant enzymes of SOD ( p < 0.001) and GPx ( p = 0.003) were significantly higher and the CAT activity ( p < 0.001) was lower after 2-month coenzyme Q10 administration compared with placebo. Data demonstrated that coenzyme Q10 supplementation at a dose of 60 mg (twice daily) is effective in reducing oxidative stress marker level (MDA) and improving antioxidant enzymes activity in glazers exposed to Cd. However, further research is needed to assess coenzyme Q10 as a possible dietary intervention in Cd-exposed workers. Trial Registration: Iranian Registry of Clinical Trials Registration Number: IRCT2016061228407N1 ( www.who.int/ictrp/network/irct/en/ ).

APA, Harvard, Vancouver, ISO, and other styles

43

Scahill, Shane. "Potion or Poison? Coenzyme Q10." Journal of Primary Health Care 5, no. 2 (2013): 164. http://dx.doi.org/10.1071/hc13164.

Full text

Abstract:

SUMMARY MESSAGE: There are no Cochrane Database Systematic Reviews (CDSR) reporting the clinical efficacy of coenzyme Q10 in statin-associated myopathy. Coenzyme Q10 is generally well tolerated. A systematic review suggests that rather than hypothesising about potential clinical benefits, large clinical studies are required to allow robust systematic review. Further, there is insufficient evidence to recommend the routine administration of concomitant coenzyme Q10 for prevention of statin-associated myopathy.

APA, Harvard, Vancouver, ISO, and other styles

44

Peng, Jingwei, Jilong Ma, Lan Zhang, and Banghao Lu. "Coenzyme Q10 attenuates airway inflammation and oxidative stress in neonatal asthmatic rats." Tropical Journal of Pharmaceutical Research 19, no. 9 (November 24, 2020): 1969–75. http://dx.doi.org/10.4314/tjpr.v19i9.24.

Full text

Abstract:

Purpose: To determine the therapeutic effect of coenzyme Q10 (CoQ10) on ovalbumin (OVA)-provoked asthma in neonatal rats.Methods: Asthma was induced by exposing neonatal rats to OVA. The levels of SOD, CAT, GPx, GSH, MDA and MPO were estimated using standard biochemical kits, while ELISA was used to measure the concentrations of Ig E and Th2 cytokines. Gene expressions were assayed with qRT-PCR, and protein expressions were determined with western blotting.Results: OVA treatment led to increases in levels of BALF inflammatory cells, lipid peroxidation, serum IgE and BALF Th2 cytokines, but it decreased antioxidant levels. Furthermore, the protein expression of NF-κB and mRNA expression levels of proinflammatory cytokines and inducible nitric oxide synthase (iNOS) were upregulated in the asthmatic rats (p < 0.05). However, coenzyme Q10 supplementation significantly decreased lipid peroxidation, and reduced inflammatory cells and IgE levels, while the antioxidant levels were enhanced (p < 0.05). Moreover, coenzyme Q10 reduced the levels of Th2 cytokines and downregulated the expressions of NF-κB, TNF-α, IL-6, and iNOS in the neonatal asthmatic rats (p < 0.05).Conclusion: Coenzyme Q10 attenuates airway inflammation and oxidative stress in neonatal asthmatic rats. Thus, coenzyme Q10 has promising therapeutic potential in the management of asthma. Keywords: Asthma, Neonatal, Coenzyme Q10, Th2, cytokines, Oxidative stress, Antiinflammation

APA, Harvard, Vancouver, ISO, and other styles

45

Bash, Hala S., and Ihsan S. Rabeea. "Coenzyme Q10 Attenuates Cisplatin-induced Nephrotoxicity Through Counteracting Oxidative Stress and Inflammation." Clinical Cancer Drugs 6, no. 1 (September 27, 2019): 41–47. http://dx.doi.org/10.2174/2212697x06666190701113043.

Full text

Abstract:

Background: Cisplatin is an anticancer drug used in the management of solid tumors, however, dose-related nephrotoxicity is one of its major problems. Agents having antioxidants, antiinflammatory and/or antiapoptotic activities may thus represent potential therapeutic options to avoid cisplatin-induced nephrotoxicity. Among these agents, coenzyme Q10 has several pharmacological properties including antioxidant, anti-inflammatory and/or anti-apoptotic effects. Objective: The current study aimed to examine whether coenzyme Q10 could attenuate cisplatininduced nephrotoxicity or not. Methods: 24 adult rats were randomly separated into three groups (8 rats per group). The first one was the control group, rats receiving vehicle (olive oil) intraperitoneally. The second group was Cisplatin treated group, rats were receiving 13 mg/kg of Cisplatin intraperitoneally as a single dose. The third group (Cisplatin + Coenzyme Q10), rats were receiving 13 mg/kg as a single intraperitoneal dose of Cisplatin and coenzyme Q10 daily for six consecutive days (10 mg/kg intraperitoneally). Results: Cisplatin caused significant increases in serum creatinine and severe histological lesions. Cisplatin treated group also showed a significant elevation in renal malondialdehyde concentration as a marker of oxidative stress; renal tumor necrosis factor-alpha concentration as a marker of inflammation; and Kidney injury molecule -1 concentration. Coenzyme Q10 significantly attenuated cisplatininduced nephrotoxicity through lowering serum creatinine and improving nephrotoxicity histological scores. Coenzyme Q10 also significantly reduced the renal concentration of MDA, TNF-α and KIM-1 relative to cisplatin treated group. Conclusions: Coenzyme Q10 has a potential nephroprotective effect against cisplatin-induced nephrotoxicity that was demonstrated by biochemical and histopathological analysis.

APA, Harvard, Vancouver, ISO, and other styles

46

Aryani, Ni Luh Dewi, Siswandono Siswodihardjo, Widji Soeratri, and Nadia Fitria Indah Sari. "Development, characterization, molecular docking, and in vivo skin penetration of coenzyme Q10 nanostructured lipid carriers using tristearin and stearyl alcohol for dermal delivery." Journal of Basic and Clinical Physiology and Pharmacology 32, no. 4 (June 25, 2021): 517–25. http://dx.doi.org/10.1515/jbcpp-2020-0512.

Full text

Abstract:

Abstract Objectives This study aims to develop coenzyme Q10 nanostructured lipid carriers (NLCs) using tristearin and stearyl alcohol as well as isopropyl palmitate (IPP) as solid and liquid lipid respectively for the dermal delivery system. Methods The coenzyme Q10 NLCs were optimized using tristearin, and stearyl alcohol in different concentrations and further characterized by dynamic light scattering (DLS) for particle size, polydispersity index (PDI), zeta potential, differential scanning calorimetry (DSC) and X-ray diffractometry for crystallinity behavior, Fourier transform infrared spectroscopy (FT-IR) for drug-lipid interaction, scanning electron microscopy (SEM) for particle shape, viscometer for viscosity, and pH meter for pH value. Furthermore, entrapment efficiency (EE), drug loading (DL), and skin penetration in vivo were also evaluated while molecular docking was conducted to examine the interaction between coenzyme Q10 and the lipids. Results The coenzyme Q10 NLCs with tristearin-IPP and stearyl alcohol-IPP as lipid matrix had <1,000 nm particle size, <0.3 PDI, less negative than −30 mV zeta potential, about 41% crystallinity index, and about six as the pH value. Moreover, the EE, DL, viscosity, and in vivo skin penetration of the NLCs using tristearin were higher compared to stearyl alcohol, however, the skin penetration depths for both NLCs were not significantly different. Furthermore, the in silico binding energy of coenzyme Q10-tristearin was lower compared to coenzyme Q10-stearyl alcohol. Both of them showed hydrophobic and van der Waals interaction. Conclusions The NLCs of coenzyme Q10 were formulated successfully using tristearin-IPP and stearyl alcohol-IPP for dermal delivery.

APA, Harvard, Vancouver, ISO, and other styles

47

Kopřiva, Vladimír, Petr Dvořák, Jana Pokorná, and Michal Žďárský. "Coenzyme Q 10 – its biochemical and related aspects." Acta Veterinaria Brno 84, no. 1 (2015): 43–46. http://dx.doi.org/10.2754/avb201585010043.

Full text

Abstract:

This review analyses the findings of biochemical and related pharmacotherapeutical aspects of coenzyme Q10. Its important role in the respiratory chain is presented. Furthermore, the article presents administration of coenzyme Q10 as a supplement within preventative measures in medicine, its pharmacotherapeutical aspects and effects in a number of diseases of various aetiologies. Concurrently, it presents the issue of mutual interactions of coenzyme Q10 and its efficacy in combining supplementation with conservative therapy of selected aetiologies.

APA, Harvard, Vancouver, ISO, and other styles

48

Hussein, Baha'a A. Abdul, and Ahmed Salim Mahmood. "THE ANTI-CATARACT EFFECT OF COENZYME Q10 IN RABBITS." International Journal of Pharmacy and Pharmaceutical Sciences 9, no. 3 (February 3, 2017): 13. http://dx.doi.org/10.22159/ijpps.2017v9i3.11391.

Full text

Abstract:

Objective: cataract is the opacity of the lens which progressively impairs the light transmission to the retina and finally prevents the vision, these opacity result from the oxidative process in the eye. The study aimed to prevent opacity of the lens by using Coenzyme Q10 as eye drops.Methods: Sodium selenite 0.01w/v injected intravitreal to the rabbit's eye to induce the disease, a group of rabbits were receive Coenzyme Q10 eye drop, and another group received distilled water, pre and post induction, cataract maturity was measured to evaluate the opacity deterioration.Results: the group of rabbits that received distilled water after induction of cataract, the opacity occurred within 48-72 h and the mean score of opacity reached to (4±0.00), while Coenzyme Q10 treated group the degree of opacity was (1.5±0.02), and there was a highly significant difference (p<0.01).Conclusion: Coenzyme q10 has an antioxidant activity when use as eye drops and this effect enable Coenzyme Q10 to prevent the opacity which is the major cause of cataract due to oxidative stress.

APA, Harvard, Vancouver, ISO, and other styles

49

Bhagavan, Hemmi N., and Raj K. Chopra. "Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations." Mitochondrion 7 (June 2007): S78—S88. http://dx.doi.org/10.1016/j.mito.2007.03.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Saryono, Saryono, Hesti Devinta, Abdul Haris Budi Widodo, and Arif Imam Hidayat. "Coenzyme q10 is potentially usedto improve lipid profile in diabetic hypercholesterolemia-induced periodontitis in the coastal area." E3S Web of Conferences 47 (2018): 07006. http://dx.doi.org/10.1051/e3sconf/20184707006.

Full text

Abstract:

Contaminated water often affects the occurrence of periodontitis in the coastal area. The diabetic hypercholesterolemia-induced periodontitis in Indonesia is very high. The use of coenzyme Q10 to treat this disease has never been investigated yet. Therefore, this study aimedto analyze the effect of coenzyme Q10 on the lipid profile of diabetic hypercholesterolemia-induced periodontitis.Twenty four rats were randomized into 6 groups (G1-G6). The groups (G1-G3) are healthy, negative and positive control group respectively. The treatment groups (G4-G6) are diabetic hypercholesterolemia-induced rats given coenzyme q10 dose of 13,5; 27 and 54 mg/kg respectively. Rats were induced by periodontitis, hypercholesterolemia and diabetes mellitus. Coenzyme Q10 was administered orally using 2 mL gastric tube once a day for 14 days. Lipid profile including triglycerides, HDL, and atherogenic index (IA) was measured enzymatically by the CHOD-PAP method. Data were analyzed by one-way ANOVA test and followed by the Least Significant Difference (LSD) post hoc test.Coenzyme Q10 with a dose of 54 mg/kgis effective in lowering triglyceride, and atherogenic index and increasing HDL level in diabetic hyperlipidemia-induced periodontitis rats model. This research supports the potential effects of coenzyme Q10 supplementation to improve lipid profile in diabetic hypercholesterolemia-induced periodontitis in the coastal area.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Coenzima Q10'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles